SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.

Ramus, SJ; Antoniou, AC; Kuchenbaecker, KB; Soucy, P; Beesley, J; Chen, X; McGuffog, L; Sinilnikova, OM; Healey, S; Barrowdale, D; et al. Ramus, SJ; Antoniou, AC; Kuchenbaecker, KB; Soucy, P; Beesley, J; Chen, X; McGuffog, L; Sinilnikova, OM; Healey, S; Barrowdale, D; Lee, A; Thomassen, M; Gerdes, AM; Kruse, TA; Jensen, UB; Skytte, AB; Caligo, MA; Liljegren, A; Lindblom, A; Olsson, H; Kristoffersson, U; Stenmark-Askmalm, M; Melin, B; SWE-BRCA; Domchek, SM; Nathanson, KL; Rebbeck, TR; Jakubowska, A; Lubinski, J; Jaworska, K; Durda, K; Złowocka, E; Gronwald, J; Huzarski, T; Byrski, T; Cybulski, C; Toloczko-Grabarek, A; Osorio, A; Benitez, J; Duran, M; Tejada, MI; Hamann, U; Rookus, M; van Leeuwen, FE; Aalfs, CM; Meijers-Heijboer, HE; van Asperen, CJ; van Roozendaal, KE; Hoogerbrugge, N; Collée, JM; Kriege, M; van der Luijt, RB; HEBON; EMBRACE; Peock, S; Frost, D; Ellis, SD; Platte, R; Fineberg, E; Evans, DG; Lalloo, F; Jacobs, C; Eeles, R; Adlard, J; Davidson, R; Eccles, D; Cole, T; Cook, J; Paterson, J; Douglas, F; Brewer, C; Hodgson, S; Morrison, PJ; Walker, L; Porteous, ME; Kennedy, MJ; Pathak, H; Godwin, AK; Stoppa-Lyonnet, D; Caux-Moncoutier, V; de Pauw, A; Gauthier-Villars, M; Mazoyer, S; Léoné, M; Calender, A; Lasset, C; Bonadona, V; Hardouin, A; Berthet, P; Bignon, YJ; Uhrhammer, N; Faivre, L; Loustalot, C; GEMO; Buys, S; Daly, M; Miron, A; Terry, MB; Chung, WK; John, EM; Southey, M; Goldgar, D; Singer, CF; Tea, MK; Pfeiler, G; Fink-Retter, A; Hansen, TV; Ejlertsen, B; Johannsson, OT; Offit, K; Kirchhoff, T; Gaudet, MM; Vijai, J; Robson, M; Piedmonte, M; Phillips, KA; Van Le, L; Hoffman, JS; Ewart Toland, A; Montagna, M; Tognazzo, S; Imyanitov, E; Issacs, C; Janavicius, R; Lazaro, C; Blanco, I; Tornero, E; Navarro, M; Moysich, KB; Karlan, BY; Gross, J; Olah, E; Vaszko, T; Teo, SH; Ganz, PA; Beattie, MS; Dorfling, CM; van Rensburg, EJ; Diez, O; Kwong, A; Schmutzler, RK; Wappenschmidt, B; Engel, C; Meindl, A; Ditsch, N; Arnold, N; Heidemann, S; Niederacher, D; Preisler-Adams, S; Gadzicki, D; Varon-Mateeva, R; Deissler, H; Gehrig, A; Sutter, C; Kast, K; Fiebig, B; Schäfer, D; Caldes, T; de la Hoya, M; Nevanlinna, H; Aittomäki, K; Plante, M; Spurdle, AB; kConFab; Neuhausen, SL; Ding, YC; Wang, X; Lindor, N; Fredericksen, Z; Pankratz, VS; Peterlongo, P; Manoukian, S; Peissel, B; Zaffaroni, D; Bonanni, B; Bernard, L; Dolcetti, R; Papi, L; Ottini, L; Radice, P; Greene, MH; Mai, PL; Andrulis, IL; Glendon, G; Ozcelik, H; OCGN; Pharoah, PD; Gayther, SA; Simard, J; Easton, DF; Couch, FJ; Chenevix-Trench, G; Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) (2012) Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Hum Mutat, 33 (4). 690 - 702. https://doi.org/10.1002/humu.22025
SGUL Authors: Hodgson, Shirley Victoria

Full text not available from this repository.

Abstract

Germline mutations in BRCA1 and BRCA2 are associated with increased risks of breast and ovarian cancer. A genome-wide association study (GWAS) identified six alleles associated with risk of ovarian cancer for women in the general population. We evaluated four of these loci as potential modifiers of ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. Four single-nucleotide polymorphisms (SNPs), rs10088218 (at 8q24), rs2665390 (at 3q25), rs717852 (at 2q31), and rs9303542 (at 17q21), were genotyped in 12,599 BRCA1 and 7,132 BRCA2 carriers, including 2,678 ovarian cancer cases. Associations were evaluated within a retrospective cohort approach. All four loci were associated with ovarian cancer risk in BRCA2 carriers; rs10088218 per-allele hazard ratio (HR) = 0.81 (95% CI: 0.67-0.98) P-trend = 0.033, rs2665390 HR = 1.48 (95% CI: 1.21-1.83) P-trend = 1.8 × 10(-4), rs717852 HR = 1.25 (95% CI: 1.10-1.42) P-trend = 6.6 × 10(-4), rs9303542 HR = 1.16 (95% CI: 1.02-1.33) P-trend = 0.026. Two loci were associated with ovarian cancer risk in BRCA1 carriers; rs10088218 per-allele HR = 0.89 (95% CI: 0.81-0.99) P-trend = 0.029, rs2665390 HR = 1.25 (95% CI: 1.10-1.42) P-trend = 6.1 × 10(-4). The HR estimates for the remaining loci were consistent with odds ratio estimates for the general population. The identification of multiple loci modifying ovarian cancer risk may be useful for counseling women with BRCA1 and BRCA2 mutations regarding their risk of ovarian cancer.

Item Type: Article
Additional Information: PMCID: PMC3458423
Keywords: Adult, BRCA1 Protein, BRCA2 Protein, Cohort Studies, Female, Genetic Predisposition to Disease, Heterozygote, Humans, Middle Aged, Mutation, Odds Ratio, Ovarian Neoplasms, Polymorphism, Single Nucleotide, Retrospective Studies
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Academic Structure > Molecular and Clinical Sciences Research Institute (MCS) > Cell Sciences (INCCCS)
Journal or Publication Title: Hum Mutat
Dates:
DateEvent
April 2012Published
PubMed ID: 22253144
Web of Science ID: 22253144
Download EPMC Full text (PDF)
Download EPMC Full text (HTML)
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/100511
Publisher's version: https://doi.org/10.1002/humu.22025

Actions (login required)

Edit Item Edit Item